For the first time scientists have successfully used CRISPR-Cas9 genome editing technology to treat malignant tumors.
Scientists from America have managed to develop a promising compound - T405, which can destroy an extremely dangerous pathogen Mycobacterium abscessus, which is resistant to existing antibiotics.
Arcutis Therapeutics has successfully tested its own drug roflumilast foam in patients with the scalp and body psoriasis.
A European regulatory body will consider Merck's tepotinib for use in certain types of tumors.
The first clinical trial of Nanoform Piroxicam manuractured by the Finnish company will begin at the end of 2020.
Scientists from Sweden Karolinska Institute have found that a common and often prescribed antidepressant can stop the growth of a malignant tumor.
Scientists have discovered a bacterial toxin that promotes tissue healing.
Scientists from the United States have found that a certain class of antibiotics could be promising for the treatment of frontotemporal dementia.
By using a new approach, scientists have developed an experimental vaccine against Toxoplasma gondii.
A study has shown that sequential administration of two different Ebola virus vaccines at regular intervals may provide the best immune response.